Insider · CIK 0001875691
Simon Dumesnil
Files at KTTA (Pasithea Therapeutics Corp.). First filing Dec 1, 2025, latest Dec 1, 2025.
In brief
Simon Dumesnil files SEC Form 4 as director at KTTA (Pasithea Therapeutics Corp.). Since Dec 1, 2025, Simon Dumesnil has reported 1 open-market buy worth $25k and 0 open-market sells worth $0, the latest filed on Dec 1, 2025.
A track record needs three past buys with six months of prices behind them; Simon Dumesnil has 0, so none is measured yet.
The newest scored trade: bought $25k of KTTA on Nov 28, 2025, filed Dec 1, 2025, scored 40 (moderate). In the last 12 months: 1 buy worth $25k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
KTTA: Pasithea Therapeutics Corp.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Pasithea Therapeutics Corp. | $25k 33,333 shares | +1333% | - |
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | KTTA Pasithea Therapeutics Corp. | AGrant or award Stock Option (right to buy)derivative | +152,783 | $0.00 | $0 | 152,783 | May 5, 2026 |
| Nov 28, 2025 | KTTA Pasithea Therapeutics Corp. | POpen-market purchase Common Stock | +33,333 | $0.75 | $25k | 35,833 | Dec 1, 2025 |
| Oct 24, 2025 | KTTA Pasithea Therapeutics Corp. | AGrant or award Stock Option (right to buy)derivative | +42,913 | $0.00 | $0 | 42,913 | Oct 27, 2025 |
| Mar 1, 2024 | KTTA Pasithea Therapeutics Corp. | AGrant or award Stock Option (right to buy)derivative | +7,500 | $0.00 | $0 | 7,500 | Mar 1, 2024 |
Questions about Simon Dumesnil
Answered from the filings on this page, as of the latest one.
Is Simon Dumesnil buying or selling?
In the last 12 months Simon Dumesnil reported 1 open-market buy worth $25k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $25k of KTTA on Nov 28, 2025. Grants, option exercises and tax withholding are not counted.
How did Simon Dumesnil's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Simon Dumesnil has 0.
Where does Simon Dumesnil file Form 4?
Simon Dumesnil has filed Form 4 at KTTA (Pasithea Therapeutics Corp.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.